Table 1 Baseline characteristics of ibrutinib patients

Demographics

 Age

70 (63-76)

74 (64-80)

74 (64-81)

0.02

 BMI

27 (24-31)

27 (24-31)

27 (23-32)

0.90

 Male

63

65

64

0.73

 White

93

94

93

0.26

 Black

3

0

2

 Unknown/Other

4

6

5

Comorbidities

 Hypertension

58

83

66

< 0.001

  Diabetes

18

32

23

0.03

 Dyslipidemia

41

67

49

< 0.001

 Chronic obstructive lung disease

14

26

18

0.023

 Cerebrovascular accidents

3

6

4

0.26

 Chronic kidney disease

10

16

12

0.22

 Liver disease

6

6

6

0.96

 Alcohol use

26

25

26

0.79

 Tobacco use

53

48

51

0.50

 Illicit drug use

3

1

3

0.42

Medications

 Statins

28

54

36

< 0.0001

 Beta blockers

21

44

28

0.001

 Neurohormal blocking agents

29

45

34

0.02

 Spironolactone

1

1

1

0.95

 Aspirin

17

52

28

< 0.001

 Warfarin

1

3

1

0.19

 Direct oral anticoagulants

7

1

5

0.10

 Calcium channel blockers

14

16

14

0.63

 Diuretics

20

30

24

0.10

 Sodium-glucose cotransporter 2

1

3

2

0.43

 Prior chemotherapy use

43

42

43

0.83

 CYP3A inhibitors

10

12

10

0.63

 CYP3A inducers

0

7

2

0.001

Initial dose

 560 mg daily

17

23

19

0.10

 420 mg daily

77

64

73

 280 mg daily

6

13

8

Cancer diagnoses

 Mantel cell lymphoma

14

19

16

0.65

 CLL^b/^cSLL

74

70

72

 Marginal zone lymphoma

1

0

1

 Waldenstrom macroglobunemia

5

3

5

 Diffuse large B-cell lymphoma

3

3

3

 Others

2

3

2